These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20930565)

  • 21. Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.
    Liu H; Frijlink HW; Huckriede A; van Doorn E; Schmidt E; Leroy O; Rimmelzwaan G; McCullough K; Whelan M; Hak E
    Vaccine; 2016 Nov; 34(48):5845-5854. PubMed ID: 27793486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvanted influenza vaccines.
    Even-Or O; Samira S; Ellis R; Kedar E; Barenholz Y
    Expert Rev Vaccines; 2013 Sep; 12(9):1095-108. PubMed ID: 24053401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommended composition of influenza virus vaccines for use in the 2006 influenza season.
    WHO
    Wkly Epidemiol Rec; 2005 Oct; 80(40):342-7. PubMed ID: 16240985
    [No Abstract]   [Full Text] [Related]  

  • 24. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.
    Neuzil KM; Tsvetnitsky V; Nyari LJ; Bright RA; Boslego JW;
    Expert Rev Vaccines; 2012 Aug; 11(8):939-47. PubMed ID: 23002975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of lyophilized and spray dried vaccine formulations.
    Preston KB; Randolph TW
    Adv Drug Deliv Rev; 2021 Apr; 171():50-61. PubMed ID: 33484735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization.
    Audouy SA; van der Schaaf G; Hinrichs WL; Frijlink HW; Wilschut J; Huckriede A
    Vaccine; 2011 Jun; 29(26):4345-52. PubMed ID: 21514345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Trends and perspectives in development of influenza vaccines].
    Sato K; Itamura S
    Nihon Rinsho; 2010 Sep; 68(9):1697-701. PubMed ID: 20845750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing cell culture-derived pandemic vaccines.
    Barrett PN; Portsmouth D; Ehrlich HJ
    Curr Opin Mol Ther; 2010 Feb; 12(1):21-30. PubMed ID: 20140813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits.
    Dehghan S; Kheiri MT; Abnous K; Eskandari M; Tafaghodi M
    Microb Pathog; 2018 Feb; 115():74-85. PubMed ID: 29223454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influenza vaccines: what do we want and how can we get it?
    Geeraedts F; Huckriede A
    Adv Exp Med Biol; 2011; 780():161-74. PubMed ID: 21842372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluarix quadrivalent vaccine for influenza.
    Graaf Hd; Faust SN
    Expert Rev Vaccines; 2015; 14(8):1055-63. PubMed ID: 26098443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and next generation influenza vaccines: Formulation and production strategies.
    Soema PC; Kompier R; Amorij JP; Kersten GF
    Eur J Pharm Biopharm; 2015 Aug; 94():251-63. PubMed ID: 26047796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a stable liquid formulation of live attenuated influenza vaccine.
    White JA; Estrada M; Flood EA; Mahmood K; Dhere R; Chen D
    Vaccine; 2016 Jul; 34(32):3676-83. PubMed ID: 27155495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain.
    Farnsworth A; Cyr TD; Li C; Wang J; Li X
    Vaccine; 2011 Feb; 29(8):1529-33. PubMed ID: 21211583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].
    Grund S; Wichmann O; Mertens T; Hengel H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Jan; 56(1):76-86. PubMed ID: 23275959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic.
    Ropero-Álvarez AM; El Omeiri N; Kurtis HJ; Danovaro-Holliday MC; Ruiz-Matus C
    Hum Vaccin Immunother; 2016 Aug; 12(8):2206-2214. PubMed ID: 27196006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pandemic influenza and the global vaccine supply.
    Fedson DS
    Clin Infect Dis; 2003 Jun; 36(12):1552-61. PubMed ID: 12802755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seasonal influenza vaccinations: specialized products for different target groups.
    Monto AS
    Vaccine; 2010 Sep; 28 Suppl 4():D14-23. PubMed ID: 20713256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.